Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sentinel Network meeting update

This article was originally published in The Tan Sheet

Executive Summary

FDA announces Feb. 15 it extended the registration deadline for a public meeting on the "Sentinel Network" to Feb. 28. FDA announced in January it scheduled a public meeting March 7 and 8 to discuss creating a private and public sector post-market network the agency says will integrate efforts to collect, analyze and disseminate product safety information to health care providers and patients (1"The Tan Sheet," Jan. 22, 2007, In Brief)...

You may also be interested in...

FDA public meeting

FDA will hold a public meeting to discuss the creation of a private and public sector post-market safety network titled "Sentinel Network," the agency announces in the Jan. 18 Federal Register. The meeting, which will be held March 7 and 8, will identify the "obstacles to facilitators and incentives for developing the data collection and risk identification and analysis components." FDA says "such a network would integrate existing and planned efforts to collect, analyze and disseminate medical product safety information to health care practitioners and patients at the point-of-care." FDA announced a similar online initiative in February 2006 for a second generation Adverse Event Reporting System (1"The Tan Sheet," Feb. 20, 2006, p. 5)...

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts